Sanofi Finalizes Acquisition of Vigil Neuroscience to Boost Neurology Pipeline
I'm PortAI, I can summarize articles.
Sanofi has completed its acquisition of Vigil Neuroscience for approximately $470 million, enhancing its neurology pipeline with VG-3927, a novel treatment for Alzheimer’s disease. This strategic move is not expected to affect Sanofi’s financial guidance for 2025. Analysts rate Sanofi stock (SNY) as a Hold with a price target of $67.00, while AI Analyst Spark rates it as Outperform, citing strong earnings and optimistic sales growth despite bearish technical momentum. Sanofi focuses on innovative medicines and vaccines, with a current market cap of $116.6 billion.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments